DOI: https://doi.org/10.22263/2312-4156.2017.5.21
Makarenko E.V.
Giant cell arteritis. Part I
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2017;16(5):21-30.
Abstract.
Giant cell (temporal) arteritis is vasculitis affecting the vessels of medium and large calibre. This disease develops in patients older than 50 years. The diagnosis of giant cell arteritis is based on clinical manifestations of the disease, the results of temporal artery biopsy and imaging methods, which include ultrasound, magnetic resonance imaging and positron emission tomography. Biopsy of the temporal artery remains to be «the gold standard» of diagnosis. It is recommended to perform temporal artery biopsy before the treatment of giant cell arteritis, but the morphological signs of vasculitis persist in 2-3 weeks after the beginning of glucocorticosteroid therapy. Laboratory studies for the diagnosis of giant cell arteritis include the determination of the amount of C-reactive protein and the rate of erythrocyte sedimentation.
Key words: giant cell arteritis, pathogenesis, clinical picture, diagnosis.
References
1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: http://dx.doi.org/10.1002/art.37715
2. Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014 Feb-Mar;48-49:73-5. doi: http://dx.doi.org/10.1016/j.jaut.2014.01.017
3. Nesher G, Breuer GS. Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update. Rambam Maimonides Med J. 2016 Oct;7(4). doi: http://dx.doi.org/10.5041/RMMJ.10262
4. Calvo-Romero JM. Giant cell arteritis. Postgrad Med J. 2003 Sep;79(935):511-5.
5. Frohman L, Wong AB, Matheos K, Leon-Alvarado LG, Danesh-Meyer HV. New developments in giant cell arteritis. Surv Ophthalmol. 2016 Jul-Aug;61(4):400-21. doi: http://dx.doi.org/10.1016/j.survophthal.2016.01.001
6. Catanoso M, Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A1, et al. Incidence, Prevalence, and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy During a 26-Year Period. Arthritis Care Res (Hoboken). 2017 Mar;69(3):430-438. doi: http://dx.doi.org/10.1002/acr.22942
7. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol. 1998 Nov;25(11):2140-5.
8. Liozon E, Ouattara B, Rhaiem K, Ly K, Bezanahary H, Loustaud V, et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S89-94.
9. Alvarez-Lafuente R, Fernández-Gutiérrez B, Jover JA, Júdez E, Loza E, Clemente D, et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis. 2005 May;64(5):780-2. doi: http://dx.doi.org/10.1136/ard.2004.025320
10. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol. 1996 Jan;23(1):112-9.
11. Haugeberg G, Bie R, Nordbø SA. Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen. J Rheumatol. 2001 Jul;28(7):1738-9.
12. Gilden D, Nagel MA. Varicella zoster virus and giant cell arteritis. Curr Opin Infect Dis. 2016 Jun;29(3):275-9. doi: http://dx.doi.org/10.1097/QCO.0000000000000258
13. Bhatt AS, Manzo VE, Pedamallu CS, Duke F, Cai D, Bienfang DC, et al. In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol. 2014 Jul;66(7):1939-44. doi: http://dx.doi.org/10.1002/art.38631
14. Watanabe R, Goronzy JJ, Berry G, Liao YJ, Weyand CM. Giant Cell Arteritis: From Pathogenesis to Therapeutic Management. Curr Treatm Opt Rheumatol. 2016 Jun;2(2):126-137. DOI: http://dx.doi.org/10.1007/s40674-016-0043-x
15. Ly KH, Régent A, Tamby MC, Mouthon L. Pathogenesis of giant cell arteritis: more than just an inflammatory condition? Autoimmun Rev. 2010 Aug;9(10):635-45. doi: http://dx.doi.org/10.1016/j.autrev.2010.05.002
16. Liegel K, Feldon S, Williams Z. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol. 2014 Mar;34(1):100-1. doi: http://dx.doi.org/10.1097/WNO.0000000000000078
17. O'Neill L, Rooney P, Molloy D, Connolly M, McCormick J, McCarthy G, et al. Regulation of Inflammation and Angiogenesis in Giant Cell Arteritis by Acute-Phase Serum Amyloid. Arthritis Rheumatol. 2015 Sep;67(9):2447-56. doi: http://dx.doi.org/10.1002/art.39217
18. Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-Tarres M. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation. 2005 Jul;112(2):264-9. doi: http://dx.doi.org/10.1161/CIRCULATIONAHA.104.520114
19. Meshkov AD, Novikov PI, Fomin VV, Moiseev SV. Giant cell arteritis: difficulties in diagnosis and treatment methods. Klin Farmakologiia Terapiia. 2014;23(2):48-54. (In Russ.)
20. Nesher G, Berkun Y, Mates M, Baras M, Nesher R, Rubinow A, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004 Mar;83(2):114-22.
21. Rüegg S, Engelter S, Jeanneret C, Hetzel A, Probst A, Steck AJ, et al. Bilateral vertebral artery occlusion resulting from giant cell arteritis: report of 3 cases and review of the literature. Medicine (Baltimore). 2003 Jan;82(1):1-12.
22. González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebro-vascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998 Aug;41(8):1497-504.
23. Staunton H, Stafford F, Leader M, O'Riordain D. Deterioration of giant cell arteritis with corticosteroid therapy. Arch Neurol. 2000 Apr;57(4):581-4.
24. Singh AG, Kermani TA, Crowson CS, Weyand CM, Matteson EL, Warrington KJ. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015 Feb;42(2):309-15. doi: http://dx.doi.org/10.3899/jrheum.140188
25. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005 Jun;112(6):1098-103.
26. Amor-Dorado JC, Llorca J, Garcia-Porrua C, Costa C, Perez-Fernandez N, Gonzalez-Gay MA. Audiovestibular manifestations in giant cell arteritis: a prospective study. Medicine (Baltimore). 2003 Jan;82(1):13-26.
27. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003 Dec;48(12):3522-31. doi: http://dx.doi.org/10.1002/art.11353
28. Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis. 2015 Jan;74(1):129-35. doi: http://dx.doi.org/10.1136/annrheumdis-2013-204113
29. Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004 Nov;83(6):335-41.
30. Schmidt J, Smail A, Roche B, Gay P, Salle V, Pellet H, et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study. Arthritis Rheumatol. 2016 Jun;68(6):1477-82. doi: http://dx.doi.org/10.1002/art.39596
31. González-Gay MA, García-Porrúa C, Salvarani C, Olivieri I, Hunder GG. Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatic. Clin Exp Rheumatol. 2000 Nov-Dec;18(6):755-9.
32. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990 Aug;33(8):1122-8.
33. Murchison AP, Gilbert ME, Bilyk JR, Eagle RC Jr, Pueyo V, Sergott RC, et al. Validity of the American College of Rheumatology criteria for the diagnosisof giant cell arteritis. Am J Ophthalmol. 2012 Oct;154(4):722-9. doi: http://dx.doi.org/10.1016/j.ajo.2012.03.045
34. Hegg R, Lee AG, Tagg NT, Zimmerman MB. Statin or nonsteroidal anti-inflammatory drug use is associated with lower erythrocyte sedimentation rate in patients with giant cell arteritis. J Neuroophthalmol. 2011 Jun;31(2):135-8. doi: http://dx.doi.org/10.1097/WNO.0b013e31820c4421
35. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occur-rence in a population-based study. Arthritis Rheum. 2001 Apr;45(2):140-5. doi: http://dx.doi.org/10.1002/1529-0131(200104)45:2<140::AID-ANR166>3.0.CO;2-2
36. Espinosa G, Tàssies D, Font J, Muñoz-Rodríguez FJ, Cervera R, Ordinas A, et al. Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin Arthritis Rheum. 2001 Aug;31(1):12-20.
37. Große K, Schmidt RE, Witte T, Baerlecken NT. Epitope mapping of antibodies against ferritin heavy chain in giant cell arteritis and polymyalgia rheumatic. Scand J Rheumatol. 2013;42(3):215-9. doi: http://dx.doi.org/10.3109/03009742.2012.733959
38. Régent A, Ly KH, Blet A, Agard C, Puéchal X, Tamas N, et al. Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. Ann Rheum Dis. 2013 Jul;72(7):1269-70. doi: http://dx.doi.org/10.1136/annrheumdis-2012-202963
39. Breuer GS, Nesher R, Nesher G. Negative temporal artery biopsies: eventual diagnoses and features of patients with biopsy-negative giant cell arteritis compared to patients without arteritis. Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1103-6.
40. Ypsilantis E, Courtney ED, Chopra N, Karthikesalingam A, Eltayab M, Katsoulas N, et al. Importance of specimen length during temporal artery biopsy. Br J Surg. 2011 Nov;98(11):1556-60. doi: http://dx.doi.org/10.1002/bjs.7595
41. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009 Mar;68(3):318-23. doi: http://dx.doi.org/10.1136/ard.2008.088351
42. Gunawardene AR, Chant H. Facial nerve injury during temporal artery biopsy. Ann R Coll Surg Engl. 2014 May;96(4):257-60. doi: http://dx.doi.org/10.1308/003588414X13814021679438
43. Murchison AP, Bilyk JR. Brow ptosis after temporal artery biopsy: incidence and associations. Ophthalmology. 2012 Dec;119(12):2637-42. doi: http://dx.doi.org/10.1016/j.ophtha.2012.07.020
44. Laria A, Lurati A, Scarpellini M1. Color duplex ultrasonography findings of temporal arteries in a case of giantcell arteritis: role in diagnosis and follow-up. Open Access Rheumatol. 2017 Mar;9:55-59. doi: http://dx.doi.org/10.2147/OARRR.S110585
45. Maldini C, Dépinay-Dhellemmes C, Tra TT, Chauveau M, Allanore Y, Gossec L, et al. Limited value of temporal artery ultrasonography examinations for diagnosisof giant cell arteritis: analysis of 77 subjects. J Rheumatol. 2010 Nov;37(11):2326-30. doi: http://dx.doi.org/10.3899/jrheum.100353
46. Blockmans D. PET in vasculitis. Ann N Y Acad Sci. 2011 Jun;1228:64-70. doi: http://dx.doi.org/10.1111/j.1749-6632.2011.06021.x
Information about authors:
Makarenko E.V. – Doctor of Medical Sciences, professor of the Chair of Internal Medicine No. 2 of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 210023, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Internal Medicine No. 2 of the Faculty for Advanced Training & Retraining. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Elena V. Makarenko.
